

ELYSE SWALLOW
Vice President

Office: 617 425 8483
Fax: 617 425 8001
elyse.swallow@analysisgroup.com

111 Huntington Avenue
14th Floor
Boston, MA 02199

Ms. Swallow applies quantitative methods to real-world problems involving evaluation, decision making, strategy, and public policy in the health care and social policy sectors. She has more than 10 years of experience leading the implementation of data analytics to support life sciences companies with real-world evidence (RWE) generation, regulatory submissions, and health technology assessments (HTAs). Ms. Swallow's expertise includes indirect treatment comparisons, survey research, database analyses, natural history studies, brand strategy, policy evaluation, RWE development, individualized medicine, and predictive analytics. Additionally, she has led health and social policy program evaluations. Ms. Swallow has worked across multiple disease areas, including rare diseases, immunology, multiple sclerosis, hematology, oncology, and renal disease. Her work has been used to inform regulatory and reimbursement decisions in US and global markets, published in numerous peer-reviewed journals, and presented at dozens of clinical and economic research conferences.

EDUCATION

2008 M.A., economics, Duke University
2007 M.P.P., Sanford School of Public Policy, Duke University
2002 B.A., philosophy, Smith College

PROFESSIONAL EXPERIENCE

2009–Present Analysis Group, Inc.
 Vice President (2019–Present)
 Manager (2015–2018)
 Associate (2013–2014)
 Senior Analyst (2011–2012)
 Analyst (2009–2010)

2006–2009 Sanford School of Public Policy, Duke University
 Research Associate (2008–2009)
 Research Analyst (2007–2008)

2002–2005 Teach For America, Furr High School, Houston ISD
 English Department Chair

PUBLICATIONS AND PRESENTATIONS

Journal Articles

- Michaud K, Conaghan P, Park SH, Lozenski K, Fillbrunn M, Khaychuk V, Swallow E, Vaile J, Lane H, Nguyen H, Pope J. Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis

of Efficacy Outcomes in Four Pooled Abatacept Trials. *Rheumatology and Therapy* Aug 2023 10(4):951-967.

- Done N, Bartolome L, [Swallow E](#), Gao W, Carley C, Wang T, Mostaghimi A. Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis. *Acta Dermato-Venereologica* Aug 2023 25;103.
- Oladapo A, Kolodny S, Vredenburg M, [Swallow E](#), Goldschmidt D, Sarathy K, Lopez P, Maitland H, Yee J. Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study. *Therapeutic Advances in Hematology* Jul 2023;14:20406207231179856.
- Kantor D, Pham T, Patterson-Lomba O, [Swallow E](#), Dua A, Gupte-Singh K. Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States. *Neurology and Therapy* Jun 2023 12(3):849-861.
- Howden C, Cook E, [Swallow E](#), Yang K, Guo H, Pelletier C, Jacob R, and Sugano K. Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for *Helicobacter pylori* infection in Japan. *Therapeutic Advances in Gastroenterology* May 2023; 16:17562848231168714.
- Kaul S, Ayodele O, Chen K, Cook E, [Swallow E](#), Rejnmark L, Gosmanova E. Association of Serum Calcium and Phosphate With Incident Cardiovascular Disease in Patients With Hypoparathyroidism. *American Journal of Cardiology* May 2023 1;194:60-70.
- Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, Done N, [Swallow E](#). Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population. *JAMA Dermatology* Apr 2023 1;159(4):411-418.
- [Swallow E](#), Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, Tencer T, Gupte-Singh K. Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison Mar 2023;71:104551.
- [Swallow E](#), Marden JR, Billmyer E, Yim E, Sun SX. Burden of Illness and Treatment Patterns Among Patients With von Willebrand Disease in US Clinical Practice *Clinical and Applied Thrombosis/Hemostasis* Jan–Dec 2023 29:10760296231177023.
- Ayodele O, Rejnmark L, Mu F, Lax A, Berman R, [Swallow E](#), Gosmanova EO. Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study. *Advances in Therapy* Nov 2022; 39(11):5013-5024.
- Kolodny S, Oladapo A, Vredenburg M, Jamieson B, [Swallow E](#), Goldschmidt D, Zichlin M, Lopez P, Davidson M, Yee J. Real-World Demographic and Clinical Characteristics of Patients Initiating Avatrombopag in the US: The Real-AVA Study. *Blood* Nov 2022 140 (Supplement 1): 13150–13151.
- Oladapo A, Kolodny S, Vredenburg M, Jamieson B, [Swallow E](#), Goldschmidt D, Zichlin M, Davidson M, Yu L, Yee J. Avatrombopag Treatment Response in Patients with Immune Thrombocytopenia: A Real-World Evidence Study. *Blood* Nov 2022 140 (Supplement 1): 10889–10890.
- Ray M, [Swallow E](#), Gandhi K, Carley C, Sikirica V, Wang T, Done N, Signorovitch J, Mostaghimi A. Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata. *Journal of Health Economics and Outcomes Research* Aug 2022; 9(2): 11-18.

- Ayodele O, Mu F, Berman R, Swallow E, Rejnmark L, Gosmanova EO, Kaul S. Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study. *Advances in Therapy* Aug 2022; 39(8): 3845-3856.
- Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, Gosmanova EO. The Risk of Chronic Kidney Disease Development in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study. *Clinical Endocrinology* Aug 2022; e-pub ahead of print 2022/08/17; doi: 10.1111/cen.14813.
- Done N, Ray M, Gao W, Wang T, Carley C, Bartolome L, Swallow E, Mostaghimi A. HSD35 Real-World Treatment Patterns Among US Adolescents with Alopecia Areata: A Retrospective Claims Analysis. *Value in Health* Jul 2022; 25(7): S486.
- DeMartino JK, Swallow E, Goldschmidt D, Yang K, Viola M, Radtke T, Kirson N. Direct health care costs associated with COVID-19 in the United States. *Journal of Managed Care and Specialty Pharmacy* Jun 2022; 06: 1-12.
- Kirson N, Swallow E, Lu J, Foroughi C, Bookhart B, DeMartino JK, Maynard J, Shivdasani Y, Eid D, Lefebvre P. Increasing COVID-19 vaccination in the United States: projected impact on cases, hospitalizations, and deaths by age and racial group. *Public Health* Jun 2022; 210: 99-106.
- Mostaghimi A, Gandhi K, Done N, Ray M, Gao W, Carley C, Wang T, Swallow E, Sikirica V. All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. *Journal of Managed Care and Specialty Pharmacy* Apr 2022; 28(4): 426-434.
- Kirson N, Swallow E, Lu J, Mesa-Frias M, Bookhart B, Maynard J, Shivdasani Y, Lefebvre P. The societal economic value of COVID-19 vaccines in the United States. *Journal of Medical Economics* Jan 2022; 25(1): 119-128.
- Gao W, Mostaghimi A, Gandhi K, Done N, Ray M, Signorovitch J, Swallow E, Carley C, Wang T, Sikirica V. Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States. *Journal of Medical Economics* Jan–Dec 2022;26(1):441-444.
- Gosmanova EO, Chen K, Ketteler M, Rejnmark L, Mu F, Swallow E, Briggs A, Sherry N, Kaul S. Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. *Advances in Therapy* Aug 2021; 38(8): 4246-4257.
- Vo P, Swallow E, Wu E, Zichlin ML, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Tiwari S, Joshi P, Ferraris M. Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain. *Journal of Medical Economics* Jul 2021; 24(1): 1900-1907.
- Gosmanova EO, Chen K, Rejnmark L, Mu F, Swallow E, Briggs A, Ayodele O, Sherry N, Ketteler M. Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. *Advances in Therapy* Apr 2021; 38(4): 1876-1888.
- Healy BC, Glanz BI, Swallow E, Signorovitch J, Hagan K, Silva D, Pelletier C, Chitnis T, Weiner H. Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. *Multiple Sclerosis Journal - Experimental, Translational and Clinical* Apr 2021; 7(2): 2055217321999070.

- Muston DRG, Monberg MJ, McLaurin K, Sackeyfio A, Hettle R, Signorovitch J, Swallow E, Gao W, Zhang S, Kalemaj I, Moore KN. Cost-effectiveness analysis of olaparib as a maintenance monotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA 1/2 mutation: A United States payer perspective. *Gynecologic Oncology* Nov 2020; 159(2): 491-497.
- Chen KS, Gosmanova EO, Curhan GC, Ketteler M, Rubin M, Swallow E, Zhao J, Wang J, Sherry N, Krasner A, Bilezikian JP. Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1–84). *The Journal of Clinical Endocrinology & Metabolism* Oct 2020; 105(10): e3557-e3565.
- Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB. A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. *Pharmacoeconomics* Nov 2020; 38(11): 1201-1218.
- Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J. Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis. *Journal of Comparative Effectiveness Research* Jun 2020; 9(10): 737-750.
- Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. *Journal of Comparative Effectiveness Research* Mar 2020; 9(4):275-285.
- Cao X, Tang D, Ratto B, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ. Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma. *Clinical Genitourinary Cancer* Feb 2020; 18(1): e37-e45.
- Vo P, Gao W, Zichlin ML, Fuqua E, Fadli E, Aguirre Vazquez M, Tarancon T, Mahieu N, Maier-Peuschel M, Rossi S, Naclerio M, Ritrovato D, Swallow E. Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain. *Journal of Medical Economics* Sep 2019; 22(9): 953-959.
- Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, Kohrman M, Korf B, Krueger D, Wong M, Sparagana S. Epilepsy treatment patterns among patients with tuberous sclerosis complex. *Journal of the Neurological Sciences* Aug 2018; 391: 104-108.
- Fishman J, Kalilani L, Song Y, Swallow E, Wild I. Antiepileptic drug titration and related health care resource use and costs. *Journal of Managed Care and Specialty Pharmacy* Sep 2018; 24(9): 929-938a.
- Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. *Journal of Managed Care and Specialty Pharmacy* May 2018; 24(6): 525-533
- Chen K, Mu F, Swallow E, Zhao J, Wang J, Krasner A, Sherry N, Signorovitch J. Comparison of 3-year estimated glomerular filtration rates between recombinant human parathyroid hormone (1-84) (RHPH[1-84])-treated patients with chronic hypoparathyroidism and a historical control cohort. *Endocrine Practice* Apr 2018; 24 (Supplement 1): 111.

- Swallow E, Messali A, Ghate S, McDonald E, Duchesneau E, Perez JR. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma. *Journal of Managed Care Specialty Pharmacy* Apr 2018; 24(4): 335-343.
- Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. *Advances in Therapy* Nov 2017; 34(11): 2452-2465.
- Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S. Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam? *CNS Drugs* Oct 2017; 31(10): 899-910.
- Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K. Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea. *Asia-Pacific Journal of Clinical Oncology* Oct 2017; 13(5): e239-e245.
- Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S. Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas. *Urology* Mar 2017; 104: 110-114.
- Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis. *Clinical Genitourinary Cancer* Aug 2017; 15(4): e573-e582.
- Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, Group DMDI, Trajectory Analysis P. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. *Neuromuscular Disorders* May 2016; 26(9): 576-583.
- Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu E. Cost impact of switching from metoprolol to nebivolol for hypertension. *American Journal of Pharmacy Benefits* May 2016; 8(3): e48-e54, 15-16.
- Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F. Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. *Journal of Comparative Effectiveness Research* May 2016; 5(3): 273-279.
- Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J. Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. *Journal of Comparative Effectiveness Research* Mar 2016; 5(2): 129-139.
- Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison. *Clinical Therapeutics* 2016 38(2): 404-412.
- Cadranel J, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P, Kageleiry A, Stein K, Degun R, Zhang J. Characteristics, treatment patterns, and survival

among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study. *Lung Cancer* Aug 2016; 98: 9-14.

- Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J, Collaborative Trajectory Analysis P. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. *PloS One* Oct 2016; 11(10): e0164684.
- Chen S, Swallow E, Li N, Faust E, Kelley C, Xie J, Wu E. Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis. *Current Medical Research and Opinion* Feb 2015; 1-30.
- Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C. Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies. *PloS One* Dec 2014; 9(12): e114264.
- Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. *Current Medical Research and Opinion* Aug 2014; 30(8): 1537-1545.
- Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ. Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension. *Current Medical Research and Opinion* Apr 2014; 30(4): 637-643.
- Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. *Pediatric Pulmonology* Mar 2013 10; 48(10): 954-961.
- Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P. Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. *Experimental Hematology & Oncology* Dec 2013; 2(1): 32.
- Gaudet D, Signorovitch J, Swallow E, Fan L, Tremblay K, Brisson D, Meyers C, Gruenberger JB. Medical resource use and costs associated with chylomicronemia. *Journal of Medical Economics* Mar 2013 03; 16(5): 657-666.
- Pike CT, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET. Prevalence and costs of osteoporotic patients with subsequent non-vertebral fractures in the US. *Osteoporosis International* Oct 2011; 22(10): 2611-2621.
- Pike C, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET. Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2-year period in the US. *Osteoporosis International* Jan 2011; 22(1): 47-56.
- Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. *Clinical Drug Investigation* Aug 2011 08; 31(9): 665-674.

Presentations

- Vo P, Swallow E, Wu E, Ellis M, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Joshi P, Ferraris M. Migraine-related healthcare resource use and costs associated with migraine chronification: a panel-based chart review. 7th EAN Congress, Virtual June 19-22, 2021.

- Chen K, Geller M, Leffler D, Meckley L, Mu F, Kponee-Shovein K, Swallow E. Disease Burden and Quality of Life Impacts in Patients With Celiac Disease on a Gluten-Free Diet: An Analysis of the ICureCeliac Registry. American College of Gastroenterology Virtual Meeting October 23-28, 2020.
- Venick R, Chen K, Carter B, Hill S, Kocoshis S, Mercer D, Mu F, Swallow E, Zhao J, Wales P, Grimm A. Identification of Factors Associated With Response to Teduglutide Within 24 Weeks Among Pediatric Patients With Short Bowel Syndrome-Associated Intestinal Failure. 11th International Pediatric Intestinal Failure and Rehabilitation Symposium, Virtual June 26, 2020.
- Dhamane A, Goldschmidt D, Swallow E, Russ C, Ferri M. Physician Preferences For Oral Anti-coagulation for Obese & Non-obese Patients With Non-valvular Atrial Fibrillation. American Heart Association Scientific Sessions 2019, Philadelphia, PA November 16-18, 2019.
- Chen K, Gao W, Wang Y, Swallow E. Predictors of high healthcare utilisers among patients with chronic hypoparathyroidism and application of machine learning methodology. ISPOR Europe 2019, Copenhagen, Denmark November 2-6, 2019.
- Vera-Llonch M, Qi CZ, Swallow E, Zichlin ML, Signorovitch J. Pro4 Impact of Enzyme Replacement Therapy on the Risk of Developing Gaucher Disease-Related Complications. ISPOR Europe 2019, Copenhagen, Denmark November 2-6, 2019.
- Cao X, Tang D, Ratto BE, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ. Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma. ASCO Annual Meeting, Chicago, IL May 31-June 4, 2019.
- Swallow E, Song J, Peeples M, Meiselbach M, Signorovitch J, Said Q, Prestifilippo J, Wong M, Northrup H, Frost M, Korf B, Sparagana S. Treatment patterns and clinical characteristics among patients with tuberous sclerosis complex related angiomyolipomas. 2017 International Research Conference on TSC & LAM, Washington, DC June 22-24, 2017.
- Vogelzang NJ, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Real-world outcomes among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (ARCC): A retrospective analysis of Medicare data. ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.
- Swallow E, Liu WJ, Wen J, Fang A, Kirson N, Birnbaum H, Bates D. Economic burden of illness for patients with traumatic brain injury resulting in chronic motor impairment. 12th World Congress on Brain Injury of the International Brain Injury Association, New Orleans, LA Mar 29-Apr 1, 2017.
- Vogelzang NJ, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Real-world economic outcomes during time on treatment among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data. AMCP Managed Care & Specialty Pharmacy Annual Meeting, Denver, CO Mar 27-30, 2017.
- Vogelzang NJ, Pal SK, Ghate S, Li N, Swallow E, Peeples M, Zichlin M, Meiselbach M, Perez JR, Agarwal N. Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data. Genitourinary Cancers Symposium, Orlando, FL Feb 16-18, 2017.

- Swallow E, Ghate S, Messali A, McDonald E, Duchesneau E, Perez JR. Cost per month of overall survival and progression-free survival: Everolimus compared with cabozantinib, nivolumab, and axitinib for metastatic renal cell carcinoma. 15th International Kidney Cancer Symposium, Miami, FL Nov 4-5, 2016.
- Vogelzang N, Pal S, Ghate S, Li N, Swallow E, Peeples M, Zichlin M, Perez JR, Agarwal N. Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: A SEER-Medicare database analysis. 15th International Kidney Cancer Symposium, Miami, FL Dec, 2016.
- Swallow E, Kelley C, Ristovska L, Signorovitch JE, McPhee F, Wygant G. Daclatasvir +asunaprevir versus sofosbuvir/ledipasvir for the treatment of chronic hepatitis c genotype 1 in Japanese patients: A matching-adjusted indirect comparison. 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, Italy Nov 7-11, 2015.
- Ghate S, Li N, Swallow E, Zichlin M, Duchesneau E, Kang B, Perez JR. Physician preference and experience with nivolumab and cabozantinib in the treatment of advanced renal cell carcinoma (aRCC) in the United States (US): A physician survey. 15th International Kidney Cancer Symposium, Miami, FL Nov 4-5, 2016.
- Nicholas J, Vogelzang, Sumanta K, Pal, Sameer Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Jose Ricardo Perez, Neeraj Agarwal. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis. IKCS 2016 Annual Meeting, Miami, FL Nov 4-5, 2016.
- Goemans NM, Signorovitch J, Swallow E, Song J, Ward SJ. Prognostic model for 1-year change in 6-minute walk distance (6MWD) in patients with duchenne muscular dystrophy (DMD). 14th International Congress on Neuromuscular Diseases, Toronto, CA July 5-9, 2016.
- Vogelzang NJ, Signorovitch JE, Swallow E, Peeples M, Koo V, Perez JR, Ghate S, Pal SK. Temporal trends in overall survival and disease-specific survival among patients with advanced renal cell carcinoma during the targeted therapy era: A SEER-Medicare analysis. ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.
- Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S. Can indirect comparison methods mitigate evolving trial populations in adjunctive antiepileptic drug trials? A propensity score matched indirect comparison of brivaracetam and levetiracetam. ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.
- Sparagana S, Swallow E, Song J, King S, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Kohrman M, Korf B, Krueger D, Wong M. Epilepsy treatment patterns among patients with tuberous sclerosis complex. 68th Annual Meeting of the American Academy of Neurology Annual Meeting, Vancouver, BC, Canada Apr 15-21, 2016.
- Krueger D, Song J, Swallow E, King S, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Korf B, Sparagana S, Wong M, Kohrman M. Subependymal giant cell astrocytoma treatment patterns among patients with tuberous sclerosis complex. 68th American Academy of Neurology Annual Meeting, Vancouver, BC, Canada Apr 15-21, 2016.
- Swallow E, Kelley C, Signorovitch J, McPhee F, Wygant G. Indirect comparison of daclatasvir+asunaprevir vs sofosbuvir/ledipasvir for HCV in Japanese patients. 25th APASL Conference, Tokyo, Japan Feb 20-24, 2016.

- Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J. Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfecting with HIV: A matching-adjusted indirect comparison. 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015, San Francisco, CA Nov 13-17, 2015.
- Cadranel J, Park K, Pless M, Bendaly E, Patel D, Sasane M, Swallow E, Galebach P, Stein K, Marinsek N, Zhang J. Characteristics and treatment patterns of ALK+ NSCLC patients who receive second-generation ALK inhibitors: A chart review study. European Cancer Congress 2015, Vienna, Austria Sept 25-29, 2015.
- Swallow E, King S, Song J, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Northrup H, Sparagana S. Demographic and Clinical Characteristics of Patients with Tuberous Sclerosis Complex in a TSC Patient Database. International TSC Research Conference, Windsor, UK Sep 10-12, 2015.
- Bendaly E, Sasane M, Zhang J, Swallow E, Macalalad AR, Patel D, Kageleiry A, Galebach P, Kercheval J, Stein K, Guérin A. Diverse characteristics of ALK+ NSCLC patients in the United States. 2015 World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.
- Swallow E, King S, Song J, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Northrup H, Sparagana S. Monitoring testing patterns among patients with tuberous sclerosis complex-related angiomyolipomas. International TSC Research Conference, Windsor, UK Sept 10-12, 2015.
- Guérin A, Sesane M, Zhang J, Swallow E, Macalalad AR, Stein K, Kageleiry A, Galebach P, Kercheval J, Patel D, Bendaly E. Physician decision-making on modifying or discontinuing crizotinib in ALK+ NSCLC: A survey of U.S. physicians. 2015 World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.
- Lim SH, Yoh KA, Lee JS, Ahn M, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Yi H, Stein K, Degun R, Park K. Real-world characteristics and outcomes for ALK+ NSCLC in Korea. 2015 World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.
- Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J. Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison. 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Vienna, Austria Apr 22-26, 2015.
- Signorovitch J, Wang J, Tan R, Thomason D, Kageleiry A, Swallow E. Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC). 2014 San Antonio Breast Cancer Symposium, San Antonio, TX Dec 9-13, 2014.
- Swallow E, Wang J, Thomason D, Tan R, Kageleiry A, Signorovitch J. Real-world treatment durations without chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC). 2014 San Antonio Breast Cancer Symposium, San Antonio, TX Dec 9-13, 2014.

- Chen Y, Swallow E, Li N, Faust E, Kelly C, Xie J, Wu EQ. Economic benefits associated with medication persistence in the treatment of hypertension: a retrospective analysis in patients who received beta-blockers. AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.
- Sparagana S, Krueger D, Swallow E, Nichols T, King S, Signorovitch J, Liu Z, Prestifilippo J, Nakagawa JA, Roberds S, Kohrman M, Frost M. Diagnosis and treatment patterns among patients with tuberous sclerosis complex-related angiomyolipomas. World TSC Conference, Washington, DC July 3-6, 2014.
- Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu EQ. Economic impact of switching from metoprolol to nebivolol for the treatment of hypertension. American Association of Nurse Practitioners 2014 National Conference, Nashville, TN June 17-22, 2014.
- Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Wang X, Moonis M, Cattaneo A, Stergiopoulos S, Kollmannsberger C. Comparative overall survival with treatment sequences for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational studies. 29th Annual Congress of the European Association of Urology, Stockholm, Sweden Apr 11-15, 2015.
- Boonen A, Kirson NY, Rao SA, Birnbaum HG, Swallow E, Yushkina Y, Jarvis J, Mease PJ, Cifaldi MA. Progression from undifferentiated spondyloarthritis to ankylosing spondylitis: Is USPA a proxy for non-radiographic axial SPA? Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.
- Birnbaum HG, Ivanova JI, Waldman T, Swallow E, Cummings AK, Clark T, Peng X, Swindle R. Assessing the impact of a Medicaid prior authorization (PA) policy for duloxetine on antipsychotic use among patients with depression. ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.
- Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J. Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir. ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.
- Colombel JF, Thakkar R, Robinson A, Yang M, Skup M, Swallow E, Betts K, Chao J, Mulani P. Comparative colorectal cancer risk in patients with ulcerative colitis treated with adalimumab versus conventional therapy. 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.
- Colombel JF, Thakkar R, Castillo M, Robinson A, Skup M, Yang M, Swallow E, Sorg R, Chao J, Mulani P. Risk of malignancy, infection, serious infection, and acute health care use in patients with Crohn's disease treated with adalimumab vs. Immunosuppressants. 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.
- Xie J, Juday T, Swallow E, Du X, Uy J, Hebden T, Signorovitch J. Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive HIV-1 patients: A matching adjusted indirect comparison of randomized trials. ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.
- Signorovitch JE, Swallow E, Kantor E, Wang X, Hass T, Klimovsky J, Metrakos P. Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-

adjusted indirect comparison of randomized trials. 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

- Sawicki G, Ayyagari R, Zhang J, Signorovitch J, Fan L, Swallow E, Shi L. Assessment of a pulmonary exacerbation risk score among cystic fibrosis patients free of recent exacerbations and not receiving recommended therapies for pulmonary care. American Thoracic Society International Conference, San Francisco, CA May 18-23, 2015.
- Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E. Compliance and persistence with nebivolol vs. Diuretics as first add-on hypertension treatment. American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition New York, NY May 19-22, 2012.
- Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu EQ. Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin. Presented at the Diabetes UK Professional Conference, 2012, Glasgow, UK, March 7–9, 2012.
- Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS. Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the US. 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) (ICPE), Chicago, IL Aug 14-17, 2011.
- Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS. Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the united states. Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC May 12-14, 2011.
- Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS. Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the United States. ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.
- Kirson N, Birnbaum H, Rao S, Swallow E, Waldman T, Dayoub E, Cifaldi M. Direct and indirect costs of spondyloarthritis patients pre-and post-diagnosi. American College of Rheumatology Annual Scientific Meeting Philadelphia, PA Oct 16-21, 2009.
- Kirson N, Birnbaum H, Rao S, Swallow K, Waldman T, Dayoub E, Cifaldi M. Diagnostic and resource use profiles before and after diagnosis of spondyloarthritis. European League Against Rheumatism Congress, Rome, Italy Jun 16-19, 2010.